TOWA Pharmaceutical Co (FRA:6QC) Research & Development: €0 Mil (TTM As of Mar. 2026)


FRA:6QC TOWA Pharmaceutical Co Ltd FRA:6QC
88 GF Score
Price €19.60
GF Value €17.54
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is TOWA Pharmaceutical Co Research & Development?

TOWA Pharmaceutical Co FRA:6QC -3.92% 88 Research & Development is €0 Mil as of Mar. 2026. GuruFocus rates FRA:6QC with a GF Score™ of 88/100 and a GF Value™ of €17.54 (Fairly Valued). The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. TOWA Pharmaceutical Co's Research & Development for the three months ended in Mar. 2026 was €0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €0 Mil.

TOWA Pharmaceutical Co  (FRA:6QC) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

TOWA Pharmaceutical Co Research & Development Related Terms

TOWA Pharmaceutical Co Research & Development Historical Data

* Premium members only.

The historical data trend for TOWA Pharmaceutical Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TOWA Pharmaceutical Co Research & Development Chart

TOWA Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

TOWA Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:6QC
88GF Score
TOWA Pharmaceutical Co Ltd FRA:6QC
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TOWA Pharmaceutical Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €0 Mil mean?
TOWA Pharmaceutical Co (FRA:6QC) has a Research & Development of €0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on TOWA Pharmaceutical Co and its competitors.
Is TOWA Pharmaceutical Co's Research & Development too high?
TOWA Pharmaceutical Co's current Research & Development is €0 Mil. Overall, TOWA Pharmaceutical Co has a GF Score™ of 88/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does TOWA Pharmaceutical Co's Research & Development compare to ZTS?
TOWA Pharmaceutical Co's Research & Development of €0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on TOWA Pharmaceutical Co and its competitors. TOWA Pharmaceutical Co's current Research & Development is €0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TOWA Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, TOWA Pharmaceutical Co (FRA:6QC) is currently considered Fairly Valued. The stock's GF Value™ is €17.54, compared to a current price of €19.60 — trading 11.7% above its estimated fair value. The current Research & Development is €0 Mil. TOWA Pharmaceutical Co's overall GF Score™ is 88/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For TOWA Pharmaceutical Co (FRA:6QC), the current Research & Development is €0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is TOWA Pharmaceutical Co (FRA:6QC) Overvalued in 2026?

Based on GuruFocus' analysis, TOWA Pharmaceutical Co stock appears to be overvalued. The current stock price of €19.60 is trading 11.7% above its estimated GF Value™ of €17.54. GuruFocus considers TOWA Pharmaceutical Co to be Fairly Valued.

Key valuation signals for FRA:6QC:

  • Research & Development: €0 Mil
  • GF Value™: €17.54 vs. price of €19.60 (11.7% above fair value)
  • GF Score™: 88/100 with 5 warning signs

No single metric tells the full story. See the FRA:6QC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

TOWA Pharmaceutical Co Business Description

Other Exchanges 4553:Japan
Address 2-11, Shinbashi-cho, Kadoma, Osaka, JPN, 571-8580
TOWA Pharmaceutical Co Ltd is a Japan based pharmaceutical company engaged in research and development, production, and marketing of generic drugs. It also provides drug consulting services for patients and their families and relatives. It organizes academic seminars for medical professionals and posts articles in journals. It participates in training for pharmacists. The company has three main plants in operation namely Osaka plant, Okayama plant, and Yamagata plant. Towa has offers more than 500 drugs to meet the diverse therapeutic requirements including lifestyle related diseases such as hypertension and diabetes, digestive system diseases, nervous system diseases and allergic diseases, vitamins and antibiotics.
88GF Score

Get the complete analysis for FRA:6QC

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€19.60
Price
€17.54
GF Value